Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia

International Journal of Hematology

Volumn 83, Issue 3, 2006, Pages 262-265

  Kunitomi, Akane ^a,c   Ishikawa, Takayuki ^b   Tajima, Kenichirou ^a   Konaka, Yoshiteru ^a   Yagita, Masato ^a  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Proteinase 3 antineutrophil cytoplasmic antibody; Reduced intensity stem cell transplantation; Therapy related leukemia; Wegener granulomatosis

Indexed keywords

AMPHOTERICIN B; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; PROTEINASE 3 NEUTROPHIL CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; CANCER REGRESSION; CASE REPORT; CHIMERA; CLINICAL FEATURE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYCOSIS; NOSE OBSTRUCTION; PERIPHERAL LYMPHOCYTE; REDUCED INTENSITY CONDITIONING; SIBLING; SYMPTOM; TRICHOSPORON CUTANEUM; WEGENER GRANULOMATOSIS; ALLOTRANSPLANTATION; CHEMICALLY INDUCED DISORDER; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; REMISSION; STEM CELL TRANSPLANTATION;

CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WEGENER GRANULOMATOSIS;

EID: 33745959466     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05148     Document Type: Article

References (19)

1. Langford CA. Wegener granulomatosis Am J Med Sci. 2001;321:76-82.
2. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002;100:82-85.
3. Ikehara S. Treatment of autoimmune diseases by hematopoietic stem cell transplantation. Exp Hematol. 2001;29:661-669.
4. Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol. 2005;128:432-459.
5. Clavio M, Gatto S, Beltrami G, et al. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia. Leuk Lymphoma. 2001;40:305-313.
6. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:1364-1372.
7. Hanel M, Friedrichsen K, Hanel A, et al. Mito-FLAG as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie. 2001;24:356-360.
8. Ziegle JS, Su Y, Corcoran KP, et al. Application of automated DNA sizing technology for genotyping microsatellite loci. Genomics. 1992;14:1026-1031.
9. Tamaki H, Mishima M, Kawakami M, et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol. 2003;78:349-356.
10. Lee K, Baglin TP, Marcus RE. Therapy-related leukaemia in Wegener's granulomatosis. Clin Lab Haematol. 1991;13:207-209.
11. Ohyashiki K, Kocova M, Ryan DH, Rowe JM, Sandberg AA. Secondary acute myeloblastic leukemia with a Ph translocation in a treated Wegener's granulomatosis. Cancer Genet Cytogenet. 1986;15:331-333.
12. Martin SJ, Audrain MA, Oksman F, et al. Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:45-48.
13. Petersen SL, Ryder LP, Bjork P, et al. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors. Bone Marrow Transplant. 2003;32:65-72.
14. Griffith LM, McCoy JP Jr, Bolan CD, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins inpatients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128:668-675.
15. Jayne DR. Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis. Cleve Clin J Med. 2002;69(suppl 2):SII110-SII115.
16. Marmont AM. Stem cell transplantation for autoimmune disorders: coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol. 2004;17:223-232.
17. Nash RA. Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens. Bone Marrow Transplant. 2003;32(suppl 1):S77-S80.
18. Hinterberger W, Hinterberger-Fischer M, Marmont A. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant. 2002;30:753-759.
19. Marmont AM, Gualandi F, van Lint MT, Bacigalupo A. Refractory Evans' syndrome treated with allogeneic transplantation followed by DLI: demonstration of a graft-versus-autoimmunity effect. Bone Marrow Transplant. 2003;31:399-402.